Skip to main content
SpringerLink
Log in

Disease-modifying treatments modulate myeloid cells in multiple sclerosis patients

  • Brief Communication
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

The role of myeloid cells in the pathogenesis of MS is determined by the polarization they acquire after activation, and mediated by release of extracellular vesicles (MVs). We assessed the effects of treatments for MS on activation and polarization of myeloid cells. MVs levels and markers of polarization of myeloid cells have been assessed at baseline and up to 6 months after the start of a MS treatment. Patients had higher levels of MVs than controls, and these increased significantly over 6 months under natalizumab. Interferon β-1a significantly decreased M1 pro-inflammatory marker IL1β and upregulated Trem2, a receptor important for debris clearance; both interferon β-1a and fingolimod decreased pro-inflammatory marker IL6. Current treatments for MS significantly modulate myeloid cells activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Carandini T, Colombo F, Finardi A et al (2015 May 26) Microvesicles: what is the role in multiple sclerosis? Front Neurol 6:111

    Article  PubMed  PubMed Central  Google Scholar 

  2. Mishra MK, Yong VW (2016 Sep) Myeloid cells - targets of medication in multiple sclerosis. Nat Rev Neurol 12(9):539–551

    Article  CAS  PubMed  Google Scholar 

  3. Hemmer B, Cepok S, Nessler S, Sommer N (2002) Pathogenesis of multiple sclerosis: an update on immunology. Curr Opin Neurol 15:227–231

    Article  PubMed  Google Scholar 

  4. Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G (2000) Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and anti-inflammatory stimuli. J Leukoc Biol 67:97–103

    Article  CAS  PubMed  Google Scholar 

  5. Bianco F, Perrotta C, Novellino L, Francolini M, Riganti L, Menna E, Saglietti L, Schuchman EH, Furlan R, Clementi E, Matteoli M, Verderio C (2009a) Acid sphingomyelinase activity triggers microparticle release from glial cells. EMBO J 28:1043–1054

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Saenz-Cuesta M, Irizar H, Castillo-Trivino T et al (2014) Circulating microparticles reflect treatment effects and clinical status in multiple sclerosis. Biomark Med 8:653–661

    Article  CAS  PubMed  Google Scholar 

  7. Choi JW, Gardell SE, Herr DR et al (2011 Jan 11) FTY720 (Fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci U S A 108(2):751–756

    Article  CAS  PubMed  Google Scholar 

  8. Guarda G, Braun M (2011 Feb 25) Staehli et al. type I interferon inhibits interleukin-1 production and inflammasome activation. Autoimmunity 34(2):213–223

    CAS  Google Scholar 

  9. Takahashi K, Prinz M, Stagi M et al (2007 Apr) TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. PLoS Med 4(4):e124

    Article  PubMed  PubMed Central  Google Scholar 

  10. Jacobs LD, Cookfair DL, Rudick RA et al (1996 Mar) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39(3):285–294

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurological Department, San Raffaele Hospital, Milan, Italy

    Gloria Dalla Costa, Giancarlo Comi & Vittorio Martinelli

  2. Division of Neuroscience, Institute of Experimental Neurology, San Raffaele Scientific Institute, Milan, Italy

    Annamaria Finardi, Livia Garzetti, Tiziana Carandini & Roberto Furlan

Authors
  1. Gloria Dalla Costa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annamaria Finardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Livia Garzetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tiziana Carandini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giancarlo Comi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vittorio Martinelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Roberto Furlan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roberto Furlan.

Ethics declarations

Conflict of interest

G. Dalla Costa, A. Finardi, L. Garzetti, T. Carandini and R. Furlan report no discosures. G. Comi has received compensation for consulting services and/or speaking activities from Bayer Schering Pharma AG, Serono Symposia International Foundation, Merck Serono International, Teva, Sanofi-Aventis and Biogen. V. Martinelli has received personal compensation for activities with Biogen, Merck Serono, Bayer Schering, TEVA and Sanofi Aventis as a speaker.

Additional information

Highlights:

• MS patients have higher extracellular myeloid vesicles than controls;

• Serum MVs increase under natalizumab and may be a biomarker for monitoring the efficacy of the drug;

• Interferon β-1a and fingolimod decrease IL6 levels, a marker of pro-inflammatory polarization of myeloid cells;

• Interferon β-1a upregulates Trem2 in myeloid cells, a receptor important for debris clearance and recovery from the attacks;

Electronic supplementary material

ESM 1

(DOC 61 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dalla Costa, G., Finardi, A., Garzetti, L. et al. Disease-modifying treatments modulate myeloid cells in multiple sclerosis patients. Neurol Sci 39, 373–376 (2018). https://doi.org/10.1007/s10072-017-3176-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-017-3176-2

Keywords

Search

Navigation